ProCE Banner Activity

Contemporary Management of HIV: Integrating New Data From CROI 2021

Watch this dynamic video module in which CCO’s expert faculty, Drs. Eric Daar and Renslow Sherer, present and discuss with one another some of the most clinically relevant new data presented at CROI 2021, including results from studies on HIV PrEP strategies, COVID-19 outcomes among PWH, ART during pregnancy/postpartum period, long-term use of current ART, and novel ART strategies in late-phase development.

Released: May 10, 2021

Expiration: May 09, 2022

No longer available for credit.

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Renslow Sherer

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Incorporate the latest data and expert insights on emerging innovative ARV treatment or prevention paradigms into the individualized care of persons with or at risk of HIV infection, as appropriate
  • Appropriately counsel patients regarding the anticipated clinical role of new and investigational ART regimens

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV Healthcare and funds for research support from Gilead Sciences, Janssen, and ViiV Healthcare.

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has received consulting fees from Amgen, Gilead Sciences, GlaxoSmithKline, Merck, and Theratechnologies; has received funds for research support from Amgen, Gilead Sciences, GlaxoSmithKline, and Merck; and has ownership interest in Gilead Sciences, Johnson & Johnson, Merck, and Pfizer.

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Genentech, Gilead Sciences, and Merck; and funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Renslow Sherer, MD, has disclosed that he has received funds for research support from Gilead Sciences.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Jennifer Swanson, MEd

Associate Managing Editor, Hematology/Oncology
Clinical Care Options, LLC

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Goal


The goal of this activity is to improve learners’ competence in providing optimal care for patients with HIV through the appropriate use of contemporary ARV regimens.